VELTASSA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VELTASSA (VELTASSA).
VELTASSA (patiromer) is a non-absorbed polymer that binds potassium ions in the gastrointestinal tract, reducing serum potassium levels by increasing fecal potassium excretion.
| Metabolism | Not metabolized; eliminated unchanged in feces. |
| Excretion | Primarily eliminated via feces as insoluble, non-absorbed polymer (80-90%); minimal renal excretion (<0.01% of administered dose as intact drug in urine), biliary excretion negligible. |
| Half-life | Not applicable due to non-systemic action; patiromer acts locally in the gastrointestinal tract and is not absorbed. Elimination half-life of the polymer is not measurable clinically. |
| Protein binding | Not absorbed, therefore protein binding is not applicable; the drug is not systemically available. |
| Volume of Distribution | Not applicable (non-systemic); Vd cannot be measured as the drug is not absorbed into systemic circulation. |
| Bioavailability | Negligible (<0.01%) after oral administration; patiromer acts locally and is not absorbed due to high molecular weight and non-digestible polymer structure. |
| Onset of Action | Oral: Onset of serum potassium reduction occurs within 4-7 hours after a single dose; clinically important reduction typically seen within 48 hours of initiating therapy. |
| Duration of Action | Duration of effect persists for at least 24 hours after steady state (achieved within 2-3 days); effect wanes within 2-3 days after discontinuation. Continuous daily dosing maintains potassium control. |
8.4 g (1 packet) orally once daily; titrate to a maximum of 25.2 g (3 packets) once daily as needed to achieve normokalemia.
| Dosage form | POWDER |
| Renal impairment | No dose adjustment is required for mild to moderate renal impairment (eGFR 30-89 mL/min/1.73 m²). For severe renal impairment (eGFR <30 mL/min/1.73 m²) or dialysis-dependent patients, use with caution; starting dose 8.4 g once daily with close monitoring of serum potassium. |
| Liver impairment | No specific dose adjustment recommended for Child-Pugh Class A or B. For Child-Pugh Class C (severe hepatic impairment), use with caution due to lack of data; no dose adjustment proposed. |
| Pediatric use | Safety and efficacy have not been established in pediatric patients (age <18 years). No recommended dosing. |
| Geriatric use | No specific dose adjustment required. Elderly patients may have decreased renal function; monitor serum potassium and renal function periodically. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for VELTASSA (VELTASSA).
| Breastfeeding | No data on presence in human milk, effects on breastfed infant, or milk production. Patiromer is a non-absorbed polymer; systemic absorption is negligible (<0.001%), so minimal excretion into breast milk is expected. Caution advised; consider developmental and health benefits of breastfeeding along with mother's clinical need. |
| Teratogenic Risk | FDA Pregnancy Category C. In animal reproduction studies, patiromer administered to pregnant rats and rabbits at doses up to 10 times the human clinical dose (6.3 g/day) showed no evidence of fetal harm. However, no adequate and well-controlled studies in pregnant women. Potential risks: maternal electrolyte disturbances (e.g., hypokalemia, hypomagnesemia) may pose fetal risk; use only if clearly needed. |
■ FDA Black Box Warning
None
| Serious Effects |
["Known hypersensitivity to patiromer","Severe constipation","Obstructive bowel disorders","Ileus or bowel perforation"]
| Precautions | ["Bowel obstruction or perforation risk in patients with gastrointestinal disorders","Severe constipation","Hypomagnesemia","Increased risk of gastrointestinal adverse events when used with certain drugs"] |
Loading safety data…
| Fetal Monitoring | Monitor serum potassium, magnesium, and electrolytes regularly, especially during pregnancy and postpartum. Assess for signs of hypokalemia or hypomagnesemia (e.g., muscle weakness, arrhythmias). Fetal monitoring per routine prenatal care; no specific fetal monitoring required due to lack of systemic absorption. |
| Fertility Effects | No human studies on fertility. In animal studies, no adverse effects on male or female fertility were observed in rats at doses up to 10 times the human clinical dose. |